Because of its versatility, CAN-2409 has the potential to be used to treat a broad range of solid tumors. Synergistic activity with standard of care radiation therapy, surgery and some forms of chemotherapy has already been shown in a number of pre-clinical and clinical settings. Furthermore, CAN-2409 presents an extremely favorable tolerability profile. More than 700 patients have been dosed to date, demonstrating the potential for combination with other therapeutic strategies without inordinate concern of overlapping adverse events.
Candel is evaluating the effects of treatment with CAN-2409 for prostate, brain, lung and pancreatic cancers in clinical trials. For more information on our studies in the clinic, please visit our Clinical Trials page.